drugset / Trial / NCT06516419
Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy
RandomizedParallel-groupSingle-blindOther
Summary
This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI This study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients. This research will be attended by 90 research subjects
Timeline
- Start
- 2024-02-13
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Concentrated secretome | Unknown | 2 ml | Intrathecal |
| Subject | Hydroquinone | Small molecule | 40 mg | Topical |
| Subject | Tranexamic Acid | Small molecule | 10 mg/ml | Intrathecal |
| Subject | Tranexamic Acid | Small molecule | 25 mg/ml | Intrathecal |
| Subject | Tretinoin | Small molecule | 0.5 mg | Topical |
| Subject | fluocinolone acetonide | Small molecule | 0.1 mg | Topical |